Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Inactivated Split-virion H1N1 Vaccine in Infants
NCT01494740Phase 2Completed
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Dec 2009
- Primary completion
- Jan 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of inactivated split-virion 2009 pandemic influenza a h1n1 vaccine in influenza A H1N1 infection (H1N1) (3 arms), sponsored by Shanghai Institute of Biological Products. Primary endpoint: Hemagglutination inhibition antibody titer at Day 35. Started Dec 2009; status: completed.
02
Drugs
inactivated split-virion 2009 pandemic influenza a h1n1 vaccine
03
Conditions
influenza A H1N1 infection (H1N1)
Beyond the preview
Go deeper on NCT01494740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01494740.